Zhong Zhao, 54371 Martling Ave, Tarrytown, NY 10591

6403675, Jun 11, 2002

Apr 30, 1998

09/070204

Wenbin Dang - Ellicott City MD
Hai-quan Mao - Towson MD
Irina Kadiyala - Baltimore MD
Kam W. Leong - Ellicott City MD
Zhong Zhao - Ellicott City MD
James P. English - Chelsea AL

Guilford Pharmaceuticals, Inc. - Baltimore MD
Johns Hopkins University - Baltimore MD

A61K 3180

523113, 523111, 523124, 524610, 528359, 528356, 528400, 424486, 424 7808, 623 1

Biodegradable, flowable or flexible polymer compositions are described comprising a polymer having the recurring monomeric units shown in formula I: wherein: each of R and Râ is independently straight or branched alkylene, either unsubstituted or substituted with one or more non-interfering substituents; L is a divalent cycloaliphatic group; Râ is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or heterocycloxy; and n is 5 to 1,000, wherein said biodegradable polymer is biocompatible before and upon biodegradation. In one embodiment, one or more of R, Râ or Râ is a biologically active substance. Amorphous compositions containing a biologically active substance, in addition to the polymer, and methods for controllably releasing biologically active substances using the compositions, are also described.

6455665, Sep 24, 2002

Jun 21, 2001

09/885085

Deborah Barnette - Ellicott City MD
James English - Chelsea AL
Keith Branham - Pelham AL
Donna Hall - Verbena AL
Reuben Land - Huntingtown MD
Doug Mink - Baltimore MD
Zhong Zhao - Ellicott City MD

Guilford Pharmaceuticals Inc. - Baltimore MD

C08G 6302

528272, 528271

The present invention provides improved processes for purifying polymer preparations by removing contaminants, such as metal contaminants. The present invention also provides improved processes for producing phosphopolymers, which can yield improved polymers in terms of molecular weight, homogeneity, consistency and purity. Polymers and polymer preparations also are provided. The present invention is time, labor and energy efficient, and thus marks an improvement over past approaches.

6800672, Oct 5, 2004

Dec 4, 2001

10/011570

Wenbin Dang - Ellicott City MD
Irina Kadiyala - Baltimore MD
Zhong Zhao - Ellicott City MD
James P. English - Chelsea AL
Hai-quan Mao - Towson MD
Kam W. Leong - Ellicott City MD

Guilford Pharmaceuticals, Inc. - Baltimore MD
Johns Hopkins University School of Medicine - Baltimore MD

A61K 3180

523113, 523111, 523124, 524610, 528356, 528359, 528400, 623 1, 424 7808, 424486

Biodegradable, flowable or flexible polymer compositions are described comprising a polymer having the recurring monomeric units shown in formula I: wherein: each of R and Râ is independently straight or branched alkylene, either unsubstituted or substituted with one or more non-interfering substituents; L is a divalent cycloaliphatic group; Râ is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or heterocycloxy; and n is 5 to 1,000, wherein said biodegradable polymer is biocompatible before and upon biodegradation. In one embodiment, one or more of R, Râ or Râ is a biologically active substance. Amorphous compositions containing a biologically active substance, in addition to the polymer, and methods for controllably releasing biologically active substances using the compositions, are also described.

6008318, Dec 28, 1999

Jun 17, 1998

9/098620

Zhong Zhao - Ellicott City MD
Hai-quan Mao - Towson MD
Kam W. Leong - Ellicott City MD

Guilford Pharmaceuticals Inc. - Baltimore MD
Johns Hopkins University - Baltimore MD

C08G 7902

528398

A process for making a phosphoester polymer comprising the recurring monomeric units of formula I: ##STR1## wherein: X is --O-- or --NR"--, where R" is H or alkyl; L is a divalent organic moiety; R' is H, alkyl, alkoxy, aryl, aryloxy, heterocyclic, or heterocycloxy; and n is between about 25 to 2,000, is described. The process comprises the steps of: (a) polymerizing in the presence of a solvent p moles of a di-XH compound having formula II: H--X--L--X--H II wherein X and L are as defined above, with q moles, where p. apprxeq. q, of a phosphorodihalo compound to form a polymer of formula I, wherein n is about 12 to 1000, having a first molecular weight Mw. sub. 1, wherein the solvent is present in an amount greater than about 5 ml of solvent per gram of compound of formula II; (b) removing at least about 25% of the solvent to form a more concentrated reaction mixture; and (c) further polymerizing the concentrated reaction mixture for an additional time sufficient to produce a polymer of formula I wherein n is between about 25 and 2,000, the polymer having a second molecular weight Mw. sub. 2, which is significantly higher than Mw. sub. 1.

2015021, Jul 30, 2015

Sep 10, 2013

14/427275

- Cambridge MA, US
Cassandra Celatka - Chesterfield MA, US
Seng H. Cheng - Wellesley MA, US
Bradford Hirth - Littleton MA, US
Andrew Good - Wallingford CT, US
Katherine Jancsics - Wilmington MA, US
John Marshall - Hopedale MA, US
Markus Metz - Waltham MA, US
Ronald K. Scheule - Hopkinton MA, US
Renato Skerlj - Newton MA, US
Yibin Xiang - Dracut MA, US
Zhong Zhao - Wayland MA, US
John Leonard - Bridgewater NJ, US
Thomas Natoli - Southborough MA, US
Elina Makino - Winchester MA, US
Herve Husson - Boston MA, US
Oxana Beskrovnaya - Southborough MA, US

GENZYME CORPORATION - Cambrdige MA

C07D 453/02
C07D 471/08
A61K 31/55
A61K 45/06
A61K 31/506
A61K 31/497
A61K 31/439
A61K 31/5377
A61K 31/496
A61K 31/551

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.